Skip to main content

Sickle Cell Disease and cannabis in Iowa

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
Capped at 4.5 grams THC…
POSSESSION
$100/yr
STATE FEE
7–21 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Iowa statute and program

The Iowa Medical Cannabidiol Program is the operating authority for Iowa patient certification. The authoritative legal text is: Iowa Code Chapter 124E: Medical Cannabidiol Act.

What the evidence says about cannabis and Sickle Cell Disease

Sickle cell disease (SCD) is a group of inherited red blood cell disorders caused by mutations in the hemoglobin gene. Red cells assume a rigid sickle shape under low-oxygen conditions, leading to chronic hemolytic anemia, episodic vaso-occlusive pain crises, stroke risk, acute chest syndrome, and progressive end-organ damage. SCD disproportionately affects people of African, Mediterranean, and South Asian descent.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Sickle Cell Disease page.

How to qualify in Iowa

The Iowa Medical Cannabidiol Program requires the following registration steps for a Sickle Cell Disease patient (or any qualifying diagnosis):

  1. Get a healthcare-practitioner certification from an Iowa-licensed provider. Under the Iowa Medical Cannabidiol Act (Iowa Code Ch. 124E), any Iowa-licensed physician, advanced registered nurse practitioner, physician assistant, or podiatrist may certify a patient for one of the enumerated debilitating medical conditions: cancer, MS, seizures, Crohn’s, AIDS or HIV, ALS, Parkinson’s, intractable autism, untreatable pain, ulcerative colitis, severe and chronic PTSD, or any terminal illness with a life expectancy of one year or less.
  2. Apply through the Iowa HHS Office of Medical Cannabidiol portal. The patient submits the Healthcare Practitioner Certification and the Patient Application through the Iowa Department of Health and Human Services (HHS) Office of Medical Cannabidiol online portal, uploads an Iowa driver license or state ID, and pays the registration fee.
  3. Pay the $100 state registration fee (or $25 reduced fee). The annual Iowa medical cannabidiol registration card fee is $100, reduced to $25 for patients enrolled in Medicaid, hawk-i, the Family Investment Program, or who have demonstrated household income at or below 200% of the federal poverty level. Caregivers register separately at the same fee structure.
  4. Receive the card and purchase from an Iowa medical cannabidiol dispensary. Iowa medical cannabidiol registration cards are issued within roughly 15 business days of complete application. With the card, patients may purchase capped doses (currently 4.5 grams of THC per 90-day rolling period under §124E.2A) from any of the licensed Iowa medical cannabidiol dispensaries. Permitted forms include capsules, tinctures, topicals, vape products, and sublinguals (no smokable flower under Ch. 124E). Iowa does not honor out-of-state medical cards.
State registration fee
$100
Physician visit (typical)
$150–$300
Certification to card
7–21 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Iowa registration steps, fees, and reciprocity rules, see the Iowa cannabis-laws page.

ICD-10 code

A certifying physician documenting Sickle Cell Disease for the Iowa medical cannabis program will typically record ICD-10 D57.1 or SNOMED-CT 417357006 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Iowa list Sickle Cell Disease as a qualifying condition for medical cannabis?

No. Iowa's qualifying-condition list does not currently include Sickle Cell Disease, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Sickle Cell Disease in Iowa have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Iowa program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a Iowa medical marijuana card for Sickle Cell Disease?

Because Iowa does not currently list Sickle Cell Disease as a qualifying condition, a card for Sickle Cell Disease alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Iowa who is registered with Iowa Medical Cannabidiol Program and willing to evaluate Sickle Cell Disease cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Iowa does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Sickle Cell Disease?

For Sickle Cell Disease, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Sickle Cell Disease lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Sickle Cell Disease should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Sickle Cell Disease and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Sickle Cell Disease; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Iowa Code Chapter 124E: Medical Cannabidiol Actaccessed May 16, 2026
  2. Iowa Department of Health and Human Services: Office of Medical Cannabidiolaccessed May 16, 2026
  3. Wikipedia: Cannabis in Iowaaccessed May 16, 2026
  4. NIH National Heart, Lung, and Blood Institute: Sickle Cell Diseaseaccessed May 15, 2026
  5. NIH NCCIH: Cannabis (Marijuana) and Cannabinoidsaccessed May 15, 2026